Item 5.02 Departure of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On March 12, 2021, Neuropathix, Inc., a Delaware corporation (the "Company"),
executed that certain second amendment to the Company's 2019 Equity Incentive
Plan to (i) replace all references to "Kannalife, Inc.," the Company's former
name, to "Neuropathix, Inc.," and (ii) increase the number of shares of Company
common stock authorized for issuance thereunder from 11,250,000 to 20,000,000
shares (the "Plan Amendment").
The Plan Amendment was approved by the Company's Board of Directors on March 12,
2021. The Plan Amendment remains subject to shareholder approval, which the
Company shall undertake to obtain as soon as reasonably practicable, but in no
even later than one year from the amendment date. In the event that the Company
does not obtain the requisite shareholder approval of the Plan Amendment within
one year, the Plan Amendment shall not be effective. A copy of the Plan
Amendment is attached hereto as Exhibit 10.1 and incorporated by reference
herein.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits
Exhibit
Number Description
10.1 Second Amendment to Neuropathix, Inc. (formerly Kannalife, Inc.) 2019
Equity Incentive Plan, effective as of March 12, 2021
2
© Edgar Online, source Glimpses
NEUROPATHIX, INC. 
